BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 68.72% | 75.92% | 94.10% | 45.38% | 45.85% |
| Total Other Revenue | -- | -- | -13.49% | 126.70% | 127.92% |
| Total Revenue | 68.72% | 75.92% | 94.10% | 45.38% | 45.85% |
| Cost of Revenue | 16.07% | 15.15% | -1.37% | -4.71% | -7.70% |
| Gross Profit | 95.21% | 109.67% | 161.00% | 91.82% | 106.00% |
| SG&A Expenses | 5.60% | 23.23% | 29.32% | 33.39% | 33.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.49% | 20.13% | 16.71% | 16.53% | 14.72% |
| Operating Income | 604.85% | 835.76% | 27,254.26% | 316.23% | 200.13% |
| Income Before Tax | -1,084.03% | -787.37% | 407.51% | 94.67% | 78.02% |
| Income Tax Expenses | -0.88% | 66.43% | 83.19% | 801.95% | 723.58% |
| Earnings from Continuing Operations | -977.18% | -756.52% | 396.87% | 92.91% | 75.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -977.18% | -756.52% | 396.87% | 92.91% | 75.53% |
| EBIT | 604.85% | 835.76% | 27,254.26% | 316.23% | 200.13% |
| EBITDA | 575.68% | 771.18% | 20,141.83% | 353.05% | 211.00% |
| EPS Basic | -737.51% | -569.44% | 390.91% | 92.87% | 76.38% |
| Normalized Basic EPS | 1,277.41% | 624.42% | 428.74% | 101.04% | 81.71% |
| EPS Diluted | -730.59% | -578.94% | 378.68% | 91.85% | 75.42% |
| Normalized Diluted EPS | 1,207.26% | 602.39% | 416.09% | 100.08% | 81.35% |
| Average Basic Shares Outstanding | 10.23% | 5.22% | 1.54% | 1.85% | 3.63% |
| Average Diluted Shares Outstanding | 11.44% | 7.81% | 5.75% | 5.07% | 5.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |